On November 16, 2026, Galvanize Therapeutics®, a commercial-stage company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease, announced the closing of an oversubscribed $130 million Series D financing. Wilson Sonsini Goodrich & Rosati advised Galvanize Therapeutics® on the transaction.
The round was led by HealthQuest Capital, a growth equity firm focused on commercial-stage healthcare companies. Olympus Innovation Ventures and Braidwell LP joined as new investors and existing investors Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company, and T. Rowe Price Associates, Inc. also participated. The financing will support Aliya's commercial expansion, clinical evidence generation, pipeline advancement, and development of next-generation pulsed electric field ablation platforms.
The Wilson Sonsini team that advised Galvanize Therapeutics® includes Jason Skolnik, Dante Matera, and James Keegan.
For more information, please see Galvanize Therapeutics'® news release.